Nanomedicine strategies for remodulating tumor-associated macrophages
10.3760/cma.j.cn121382-20230815-00502
- VernacularTitle:基于肿瘤相关巨噬细胞调控的纳米药物研究进展
- Author:
Wenyue GAO
1
;
Guilei MA
Author Information
1. 中国医学科学院 北京协和医学院生物医学工程研究所，天津 300192
- Keywords:
Tumor-associated macrophages;
Nanomedicine;
Tumor;
Immunotherapy
- From:
International Journal of Biomedical Engineering
2023;46(5):384-389
- CountryChina
- Language:Chinese
-
Abstract:
Tumor-associated macrophages (TAMs) are the main immune cells in the tumor microenvironment, mainly divided into M1 type macrophages which are pro-inflammatory and anti-tumor and M2 type macrophages that are anti-inflammatory and can promote the growth of tumor. M2 macrophages play a crucial role in the occurrence, development and metastasis of tumor, are often closely related to poor prognosis, and have become an important target of tumor immunotherapy. Nanomedicine can achieve specific targeting of TAMs and improve drug safety. Therefore, the use of nanomedicine to regulate TAMs has broad application prospects. Using nanoparticles to deplete TAMs, inhibit their recruitment or reprogram M2 macrophages into M1 macrophages, or using TAMs to deliver nanomedicine has shown great potential for clinical application. In this paper, the role of TAMs-based nanomedicine in tumor immunotherapy was elaborated, and the existing problems and suggestions were discussed.
